Skip Nav Destination
1-20 of 24
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)
Kelly J. Norsworthy, MD, Alexander E Perl, MD, Martin Carroll, MD, Selina M. Luger, MD, Kenneth S. Bauer, PharmD, PhD, Michael L. Tidwell, CRNP, Dina Ioffe, BA, Maria R. Baer, MD, Edward A. Sausville, MD, PhD, Ivana Gojo, MD
Blood (2011) 118 (21): 1557.
Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo
Yun Dai, Shuang Chen, Rena Shah, Xin-Yan Pei, Li Wang, Jorge A. Almenara, Lora B. Kramer, Paul Dent, Steven Grant
Blood (2011) 117 (6): 1947–1957.
Includes: Supplemental data
David Devlin, Medical, Student, Eva Szegezdi, Post-Doctoral, Researcher, Paavilainen Tanja, Student, Orsolya Orosz, Student, Michael O'Dwyer, MD, FRCPath, Michael Carty, Senior, Lecturer, Afshin Samali, PhD, Séverine Cruet Hennequart, PhD
Blood (2010) 116 (21): 4465.
Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells
Sylvain Thepot, Elodie Lainey, Marie Sebert, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer
Blood (2010) 116 (21): 2173.
CRLF2/JAK Signaling Confers Susceptibility to JAK Inhibitors and Small Molecule Inhibitors of Protein Kinase C.
Nathan West, Akinori Yoda, Ph.D., Sabina Chiaretti, Kartik Mani, Robin Foà, James Bradner, David M Weinstock, MD
Blood (2009) 114 (22): 3767.
Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines
Anita K Gandhi, Jian Kang, Lori Capone, Ling-Hua Zhang, Blake Bartlett, Dennis Pietronegro, Annette Ervin-Haynes, Peter H Schafer
Blood (2008) 112 (11): 4990.
The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.
Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Stephane de Botton, Pierre Fenaux, Guido Kroemer
Blood (2008) 112 (11): 1655.
Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.
Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Wolf-Karsten Hofmann, Pierre Fenaux, Guido Kroemer
Blood (2008) 112 (11): 1656.
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cells
Yun Dai, Shuang Chen, Xin-Yan Pei, Jorge A. Almenara, Lora B. Kramer, Charis A. Venditti, Paul Dent, Steven Grant
Blood (2008) 112 (6): 2439–2449.
Includes: Supplemental data
Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.
Anita K. Gandhi, PhD, Jian Kang, BS, Ling-Hua Zhang, PhD, Blake Bartlett, PhD, Peter H. Schafer, PhD, David I. Stirling, PhD
Blood (2007) 110 (11): 4516.
Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.
Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD
Blood (2007) 110 (11): 2438.
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
Blood (2007) 110 (6): 2092–2101.
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation
Blood (2007) 109 (10): 4415–4423.
DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.
Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD
Blood (2006) 108 (11): 3392.
Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD
Blood (2006) 108 (11): 2649.
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
Clinical Trials & Observations
Deepa Sampath, Jorge Cortes, Zeev Estrov, Min Du, Zheng Shi, Michael Andreeff, Varsha Gandhi, William Plunkett
Blood (2006) 107 (6): 2517–2524.
Tachpyridine, a metal chelator, induces G 2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation
JoLyn Turner, Constantinos Koumenis, Timothy E. Kute, Roy P. Planalp, Martin W. Brechbiel, Dillon Beardsley, Brooke Cody, Kevin D. Brown, Frank M. Torti, Suzy V. Torti
Blood (2005) 106 (9): 3191–3199.
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
Yun Dai, Mohamed Rahmani, Xin-Yan Pei, Payal Khanna, Song Iy Han, Clint Mitchell, Paul Dent, Steven Grant
Blood (2005) 105 (4): 1706–1716.
Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK.
Yun Dai, Ph.D., Mohamed Rahmani, Ph.D., Xin-Yan Pei, M.D., Payal Khanna, Paul Dent, Ph.D., Steven Grant, M.D.
Blood (2004) 104 (11): 3403.
Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells
Blood (2004) 103 (7): 2761–2770.